Former senator Ben Sasse has been candid about a dire pancreatic cancer diagnosis and is now reporting dramatic benefit from an experimental pill, daraxonrasib; this article explains the trial results, how the drug works, what doctors are saying about side effects and potential, and how Sasse and his care team view the progress as they push for broader testing and approval.
When Sasse first learned his cancer had spread, doctors gave him a very short window to live, and the mood around him shifted overnight. He enrolled in a clinical trial for daraxonrasib, an oral drug aimed at a specific genetic driver behind many aggressive tumors. The change in his symptoms and scans has been striking enough that he is speaking publicly about the treatment.
“I have much, much less pain than I had four months ago when I was diagnosed, and I have a massive 76% reduction in tumor volume over the last four months,” Sasse told “60 Minutes” in a recent interview. Those are the kind of numbers that make oncologists pay attention, especially in a disease that rarely responds so well. For patients and families, measurable shrinkage like that is not just a medical detail; it changes daily life.
Daraxonrasib targets a molecular switch known as RAS, a key growth signal that drives many pancreatic tumors. “In pancreatic cancer, that switch is stuck in the ‘on’ position in the vast majority of tumors, constantly telling the cancer cells to grow and spread,” said Sarbajit Mukherjee, M.D., a gastrointestinal medical oncologist. The drug is designed to latch onto RAS and dampen that signal, slowing or shrinking the tumor.
Late-stage trial data released by the company behind daraxonrasib compared the new therapy to standard chemotherapy in patients who had already failed prior treatments. Patients receiving the experimental drug lived a median of 13 months, compared with roughly six months for those who continued chemo alone. That sort of difference is large in the world of metastatic pancreatic cancer, where gains are often measured in weeks, not months.
“This is the first-of-its-kind targeted therapy for pancreatic cancer,” said Dr. Marc Siegel, a senior medical analyst. “The drug is in the final stages of clinical trials, where it has been shown to double the survival of those previously treated for metastatic pancreatic cancer.” Those words capture why clinicians are calling this a potential turning point rather than a small incremental advance.
Oncologists who treat this disease every day say daraxonrasib feels different from other therapies that only marginally slow progression. “From my perspective, as someone who treats pancreatic cancer every day, daraxonrasib is the first targeted pill in this disease that truly feels like a step change rather than a small incremental improvement,” Mukherjee said. He added that the drug could enable more personalized approaches that move beyond one-size-fits-all chemo.
Combining daraxonrasib with frontline chemotherapy is already under study, and early signals suggest that using it earlier may produce deeper tumor shrinkage. Trials will decide whether the pill becomes part of initial therapy or remains a second-line option when chemo stops working. If approved, daraxonrasib would offer a new route for patients who currently face very limited choices.
No treatment is free of side effects, and daraxonrasib is no exception, though it is generally better tolerated than traditional chemotherapy. “The ones we see most often include rash, diarrhea, mouth sores and fatigue, with patients needing regular blood tests and close follow‑up while on treatment,” Mukherjee said. Trial teams say most adverse effects have been managed with dose tweaks and supportive meds.
“The limitations are important to be transparent about — it is still not yet FDA‑approved, and it is not a cure,” Mukherjee noted. He warned that cancers frequently evolve resistance to targeted drugs over time, meaning durable remissions are not guaranteed. Still, turning an aggressive, previously untargetable tumor into a controllable chronic condition would be a major win.
Sasse has also spoken about the role of faith and reflection during this battle, and his comments have resonated with many who face similar diagnoses. “It’s weird to be in your early 50s and get a terminal diagnosis, and people all of a sudden act like you’re 93 or 94, and you have a lot of wisdom,” he said. “I don’t know that I have a lot of wisdom, but I have a lot of things that I think we should be reflecting on together.”
The spotlight on Sasse’s case is likely to accelerate interest and enrollment in ongoing trials, but experts stress the need for careful science and broader patient data. Researchers must confirm the benefit across diverse groups and pin down which patients stand to gain the most. For families navigating this disease, the combination of meaningful clinical responses and a clearer path toward approval offers a rare dose of hope.
